Capstone initiates Coverage on Inverness Medical Innovations (IMA) with a Buy
More News related to IMA
- Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
- To Manage Weight Over the Holidays, Experts From Alere Say Enjoy, Indulge a Little and Don't Diet!
- OraSure Tech (OSUR) Settles Patent Infringement Suit with Inverness (IMA), Inverness Switzerland, and Church & Dwight (CHD)
- OraSure Tech (OSUR) Settles Patent Infringement Suit with Inverness (IMA), Inverness Switzerland, and Church & Dwight (CHD)
- Alere Secures Prestigious NCQA Accreditation for Wellness & Health Promotion
More News related to New Coverage
- Dahlman Rose Initiates Coverage on Independent Oil & Gas Stocks
- Sandler O'Neill Initiates Coverage on AON Corp. (AON) with a Hold
- Ameriprise Financial Initiates Coverage on Janus Capital (JNS) with a Buy
- BGB Securities Initiates Coverage on International Flavors & Fragrances (IFF) with a Buy
- Barrington Research Initiates Coverage on Masimo (MASI) with an Outperform
Capstone initiates coverage on Inverness Medical Innovations (NYSE: IMA) with a Buy. Price target $47.
To see more analyst ratings on IMA Click Here.
Inverness Medical Innovations, Inc. engages in the development, manufacture, and marketing of consumer and professional medical diagnostic products, as well as a range of vitamins and nutritional supplements
Related Categories
New CoverageStocks Mentioned
+0.17Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
